SMPD2

Across TCGA pan-cancer cohorts, SMPD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMPD2 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMPD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMPD2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where SMPD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.771	1.000	.031	5	view →
GBM	DFS	Quartile	All	0.494	0.260	.021	4	view →
LUAD	DFS	Tertile	All	0.711	1.000	.013	3	view →
LSCC	DFS	Tertile	All	0.866	0.401	.015	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SMPD2–CCRCC (DFS)

Open the CCRCC breakdown →